View Pages
Abridge CEO Shiv Rao explains how AI partnerships, including with Eli Lilly, help providers deliver faster, cheaper, and more attentive care by adapting AI models for clinicians.
Editorial companion
Shiv Rao of Abridge told Bloomberg that companies like Eli Lilly are adapting conversational artificial intelligence (AI) to make doctors more present with patients while cutting downstream costs, a small-sounding shift with big implications. For investors, this is evidence pharma is buying optionality outside pill development, treating workflow tech as a way to reduce friction and boost outcomes rather than chasing another blockbuster. Partnerships like this reframe where future margin expansion might come from for large drugmakers.
View Pages